Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congressman Calls For Resignation Of U.S. FDA Commissioner In Wake Of Latest Chinese Safety Scare

This article was originally published in PharmAsia News

Executive Summary

A key House subcommittee chairman has called for the resignation of U.S. FDA Commissioner Andrew von Eschenbach in the wake of reports that FDA failed to inspect a Chinese API manufacturer that may be linked to adverse reactions in patients taking injectable heparin, a blood thinner marketed by Baxter Healthcare (PharmAsia News, Feb. 14, 2008)

You may also be interested in...



With Overstretched FDA, Companies Advised To Conduct Their Own Foreign Inspections – Former FDA Chief Counsel

FDA's failure to inspect a Chinese API manufacturer that may be linked to the heparin safety issue will "drive home" to the pharmaceutical industry the need to ensure the safety of the ingredients in drug products, according to an industry expert

With Overstretched FDA, Companies Advised To Conduct Their Own Foreign Inspections – Former FDA Chief Counsel

FDA's failure to inspect a Chinese API manufacturer that may be linked to the heparin safety issue will "drive home" to the pharmaceutical industry the need to ensure the safety of the ingredients in drug products, according to an industry expert

Heparin Investigation Highlights Foreign Inspection Gap – Former FDA Officials

Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel